PTO/SB/21 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE and to a collection of information unless it displays a valid OMB control number

ne Paperwork Reduction Act of 1995, no persons are required to res

1

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

porta to a coaccaon or anomiation	Turress it displays a valid Olvid Control numbe
Application Number	10/643589
Filing Date	August 18, 2003
First Named Inventor	Debra D. Pittman
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	WYTH-P01-002

ENCLOSURES (Check all that apply)					
Fee Transmittal Form	Drawing(s)	After Allowance Communication to Group			
Fee Attached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences			
Amendment/Reply	Petition	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)			
After Final	Petition to Convert to a Provisional Application	Proprietary Information			
Affidavits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address	Status Letter			
Extension of Time Request	Terminal Disclaimer	Other Enclosure(s) (please identify below):			
Express Abandonment Request	Request for Refund				
x Information Disclosure Statement	CD, Number of CD(s)				
Certified Copy of Priority Document(s)					
Response to Missing Parts/ Incomplete Application	Remarks				
Response to Missing Parts					
under 37 OF N 1.32 OF 1.33					
SIGNA	TURE OF APPLICANT, ATTORNEY, OF	RAGENT			
	Anita Varma - 43 221				
Signature Anch	Varne				
Date February 25, 2004					
Express Abandonment Request X Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNA Firm or Individual name Signature Anita Varma - 43,2	Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) Remarks TURE OF APPLICANT, ATTORNEY, OF	Other Enclosure(s) (please identify below):			

I hereby certify that this correspondence is	s being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in
an envelope addressed to: Commissione	r for Patents, P.O. Box 1450, Alexandria, VA, 22313-1450, on the date shown below.
Dated: 2/25/04	or for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below. Signature: Cana Soldano (Crena Soldano)



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the data shown below.

Dated 25/04

Signature: (Crena Soldano)

Docket No.: WYTH-P01-002

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Pittman et al.

Application No.: 10/643589

Filed: August 18, 2003 Art Unit: 1646

For: COMPOSITIONS AND METHODS FOR

TREATING RAGE-ASSOCIATED

DISORDERS

Examiner: Not Yet Assigned

Confirmation No.: 3988

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of each reference on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

Application No.: 10/643589 Docket No.: WYTH-P01-002

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. WYTH-P01-002. A duplicate copy of this paper is enclosed.

Dated: February 25, 2004

Respectfully submitted,

Anita Varma

Registration No.: 43,221 ROPES & GRAY LLP One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant

PTO/SB/08a/b (06-03)
Approved for use through 07/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Su	Substitute for form 1449A/B/PTO			Complete if Known		
				Application Number	10/643589	
	VFORMATION	1 DI	SCLOSURE	Filing Date	August 18, 2003	
S	TATEMENT	3Y /	APPLICANT	First Named Inventor	Debra D. Pittman	
				Art Unit	N/A	
	(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	1	of	3	Attorney Docket Number	WYTH-P01-002	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	AA	US-5,864,018	01-26-1999	Schering Aktiengesellschaft	r garoo Appear	
	AB	US-5,891,341	04-06-1999	The Picower Institute for Medical Research		
	AC	US-6,007,865	12-28-1999	Alteon Inc.; The Picower Institute for Medical Research		
	AD	US-6,380,165-B1	04-30-2002	The Picower Institute for Medical Research		
	AE	US-6,440,749-B1	08-27-2002	Alteon, Inc.; The Picower Institute for Medical Research		
	AF	US-5,656,261	08-12-1997	The Picower Institute for Medical Research; Alteon Inc.		
	AG	US-5,853,703	12-29-1998	The Picower Institute for Medical Research; Alteon Inc.		
	AH	US-2001/0039256-A1	11-08-2001	Stern, et al.		
	ΑI	US-2001/0053357-A1	12-20-2001	Stern, et al.		
	AJ	US-2002/0002203-A1	01-03-2002	Rahbar		
	AK	US-2002/0013256-A1	01-31-2002	Rahbar, et al.		
	AL	US-2002/0022234-A1	02-21-2002	Al-Abed, et al.		
	AM	US-2002/0037496	03-28-2002	Jacobson, et al.		
	AN	US-2002/0077293-A1	06-20-2002	Cahoon, et al.		
	AO	US-2002/0082273-A1	06-27-2002	Bush, et al.		
	AP	US-2002/0086282-A1	07-04-2002	Pillarisetti, et al.		
	AQ	US-2002/0106726-A1	08-08-2002	Schmidt, et al.		
	AR		08-22-2002	Stern, et al.		
<u> </u>	AS	US-2002/0122799-A1	09-05-2002	Stern, et al.		

		FOREI	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
	ВА	WO-00/18970-A1	04-06-2000	Asahi Kasei Kogyo Kabushiki Kaisha		
	BB	WO-00/20458-A1	04-13-2000	The Trustees of Columbia University in the City of New York		
	ВС	WO-00/20621-A1	04-13-2000	The Trustees of Columbia University in The City of New York		
	BD	WO-01/05422-A1	01-25-2001	Biomerieux Stelhys		
	BE	WO-01/12598	02-22-2001	The Trustees of Columbia University in The City of New York		
	BF	WO-01/18060-A1	03-15-2001	Toray Industries, Inc.		\Box
	BG	WO-01/029269	04-26-2001	Case Western Reserve University		
	ВН	WO-01/76584	10-18-2001	City of Hope		

Examiner			Date		
Signature			Considered	ŀ	

PTO/SB/08a/b (06-03)

Approved for use through 07/31/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	stitute for form 1449A/B/I	РТО			Complete if Known
				Application Number	10/643589
l IN	IFORMATIO	N DI	SCLOSURE	Filing Date	August 18, 2003
S	TATEMENT	BY A	APPLICANT	First Named Inventor	Debra D. Pittman
				Art Unit	N/A
	(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	WYTH-P01-002

BI	WO-01/079849		Trans Tech Pharma	
BJ	WO-01/086002	11-15-2001	Genetics Institute, LLC; The	
			Rockefeller University	
ВК	WO-01/92210-A1	12-06-2001	Trans Tech Pharma	
BL	WO-01/092892			
BM	WO-02/30889	04-18-2002	The Trustees of Columbia	
			University in The City of New	
			York	
BN	WO-02/030889	04-18-2002	The Trustees of Columbia	
			University in The City of New	
ВО	WO-02/066978	00.00.000	York	
BP	WO-02/068978	08-29-2002 09-06-2002	Reddy US Therapeutics, Inc. Fraunhofer-Gesellschaft Zur	
BP	VVO-02/060636-A1	09-06-2002	Forderung Der Angewandten	
			Forschung E.V.	
BQ	WO-02/14519-A1	02-21-2002	The Trustees of Columbia	
5%	140 02/14010/11	02-21-2002	University in The City of New	
			York	
BR	WO-97/26913-A1	07-31-1997	The Trustees of Columbia	
			University in The City of New	
			York	
BS	WO-97/39125-A1	10-23-1997	Schering Aktiengesellschaft	
			Patente	
BT	WO-98/22138-A1	05-28-1998	The Trustees of Columbia	
			University in The City of New	
	140 00/1007/ 4/	20.47.4000	York	ļ
BU	WO-98/40071-A1	09-17-1998	The General Hospital	
BV	WO-99/07402-A1	02-18-1999	Corporation The Trustees of Columbia	
l lev	VVO-99/07402-A1	02-18-1999	University of The City of New	
			York	
BW	WO-99/18987-A1	04-22-1999	The Trustees of Columbia	
	VVO-35/1030/-A1	04-22-1555	University of The City of New	
			York	
ВХ	WO-99/45907-A2	09-16-1999	The General Hospital	
			Corporation	
BY	WO-99/54485-A1	10-28-1999	The Trustees of Columbia	
			University in The City of New	
			York	
BZ	WO-97/39121-A1	10-23-1997	Schering Aktiengesellschaft	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE	DOCUMENTS				
	miner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
Examiner Signature			Date Considered				

PTO/SB/08a/b (06-03)

Approved for use through 07/31/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	Substitute for form 1449A/B/PTO			Complete if Known		
	INFORMATION DIGGLOOUSE			Application Number	10/643589	
IN	IFORMATION	N DIS	CLOSURE	Filing Date	August 18, 2003	
S	STATEMENT BY APPLICANT			First Named Inventor	Debra D. Pittman	
				Art Unit	N/A	
(Use as many sheets as necessary)			necessary)	Examiner Name	Not Yet Assigned	
Sheet	3	of	3	Attorney Docket Number	WYTH-P01-002	

CA	Schmidt, et al., "The multiligand receptor RAGE as a progression factor amplifying immune	
	and inflammatory responses," J. Clin. Invest. 949-955, Vol. 108(7), October 2001.	İ

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	

¹Applicant's unique citation designation number (optional). 2Applicant is to place a check mark here if English language Translation is attached.